| 期刊簡介 | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Neuropeptides LetPub Score 6.4
50 ratings
Rate
Reputation 7.5 Influence 4.9 Speed 9.7 | ||||||||||||||||||||||||||||
| 期刊簡稱 | NEUROPEPTIDES | ||||||||||||||||||||||||||||
| ISSN | 0143-4179 | ||||||||||||||||||||||||||||
| E-ISSN | 1532-2785 | ||||||||||||||||||||||||||||
| h-index | 63 | ||||||||||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||||||||||
| 自引率 (2023-2024) | 8.00%自引率趨勢 | ||||||||||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||||||||||
| 官方網站 | http://www.journals.elsevier.com/neuropeptides/ | ||||||||||||||||||||||||||||
| 在線稿件提交 | http://ees.elsevier.com/npep/default.asp?pg=preRegistration.asp | ||||||||||||||||||||||||||||
| 開放訪問 | No | ||||||||||||||||||||||||||||
| 出版商 | Churchill Livingstone | ||||||||||||||||||||||||||||
| 主題領域 | 医学 | ||||||||||||||||||||||||||||
| 出版國/地區 | SCOTLAND | ||||||||||||||||||||||||||||
| 發行頻率 | 隔月刊行 | ||||||||||||||||||||||||||||
| 創刊年 | 1980 | ||||||||||||||||||||||||||||
| 每年文章數 | 53每年文章數趨勢 | ||||||||||||||||||||||||||||
| 黃金OA百分比 | 16.78% | ||||||||||||||||||||||||||||
| Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q3
| ||||||||||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0143-4179%5BISSN%5D | ||||||||||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: >12 Week(s), or Invited contributions | ||||||||||||||||||||||||||||
| 競爭力 * | 來自作者的數據: Moderate | ||||||||||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||||||||||
| *所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||||||||||
|
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [Neuropeptides] 的評論 | 撰寫評論 |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 18:28:25 評論於 Generally, a research article will suffice |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 16:50:35 評論於 Generally includes sections such as title, abstract, introduction, methods, results, conclusions, figures (including figure titles and captions), acknowledgements, conflicts of interest, and references |
| 作者: Darlene Pepys 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 15:21:04 評論於 What are the main components of a research article? |
| 作者: 魂魄彦露 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 17:21:38 評論於 What types of SCI articles are most suitable for beginners in scientific research to practice? |
| 作者: 筑阳惜珊 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2020-01-07 09:12:06 評論於 Review speed: 3.0 | Submission acceptance rate: 50.0 Sharing of Experience: Editors will invite 6-9 external reviewers, and these reviewers will carefully review the article. If you are in a hurry to graduate, we do not recommend submitting to this journal |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-18 14:52:25 評論於 The continuous downward trend, will it break 2 in the end? It has fallen quite a bit in just one year, even if it's just 0.1 point, it should still be cherished |
| 作者: 是迎蕊吖 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2015-08-11 14:20:55 評論於 Review speed: 1.0 Experience sharing: A professional journal on neuropeptides, accepted after minor revisions, reviewers are meticulous and constructive, editors are also very enthusiastic |
| 作者: 77953694@qq.com 領域: 医药科学 審稿時間: 1.0 month(s) 結果: 修改後接受 撰寫評論 |
2015-08-11 12:28:33 評論於 The reviewers are rigorous. Their opinions are pertinent. The editors are also very enthusiastic. |
| 作者: 万花韶敏 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2014-11-27 18:59:23 評論於 Review speed: 2.0 | Submission hit rate: 75.0 Experience sharing: The magazine editors and reviewers are very nice, the articles are relatively good, and clinical articles are also accepted |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2013-07-01 12:34:50 評論於 It's already crossed 2 points, will it be slightly higher next year, there is hope |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us